Cargando…

Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma

Renal cell carcinoma (RCC) is the third most common genitourinary cancer in the USA. Despite recent advances in the treatment for advanced and metastatic clear cell RCC (ccRCC), the 5-year relative survival rate for the distant disease remains at 12%. Cabozantinib, a tyrosine kinase inhibitor (TKI),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Keon Young, Hefti, Hunter O, Liu, Peng, Lugo-Cintrón, Karina M, Kerr, Sheena C, Beebe, David J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8730366/ https://www.ncbi.nlm.nih.gov/pubmed/34931665 http://dx.doi.org/10.1093/intbio/zyab018

Ejemplares similares

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
por: Vecchio, Sharon J. Del, et al.
Publicado: (2018)

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017)

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
por: Rathi, Nityam, et al.
Publicado: (2020)

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
por: Bersanelli, Melissa, et al.
Publicado: (2017)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
por: Iuliani, Michele, et al.
Publicado: (2021)

Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma
por: Nakagawa, Takashi, et al.
Publicado: (2022)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
por: Colomba, Emeline, et al.
Publicado: (2022)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

A bioengineered organotypic prostate model for the study of tumor microenvironment-induced immune cell activation
por: Kerr, Sheena C, et al.
Publicado: (2020)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
por: Grassi, Paolo, et al.
Publicado: (2016)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
por: Bersanelli, Melissa, et al.
Publicado: (2018)

An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives
por: Iaxx, Romain, et al.
Publicado: (2022)

Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
por: Zhang, Qing, et al.
Publicado: (2017)

Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma
por: Lue, Hui-wen, et al.
Publicado: (2021)

Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma
por: Gerendash, Benjamin S, et al.
Publicado: (2017)

Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma
por: Uche, An, et al.
Publicado: (2019)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
por: Grassi, Paolo, et al.
Publicado: (2016)

Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib
por: Boustany, Johnny, et al.
Publicado: (2020)

Cabozantinib‐induced renal thrombotic microangiopathy
por: La Manna, Gaetano, et al.
Publicado: (2017)

Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis
por: Lemke, Emily A., et al.
Publicado: (2019)

Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
por: Lacy, Steven, et al.
Publicado: (2018)

Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports
por: Négrier, Sylvie, et al.
Publicado: (2018)

Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study
por: Pal, Sumanta K., et al.
Publicado: (2021)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
por: Wang, Hao, et al.
Publicado: (2022)

Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma(1)
por: Sharma, Akanksha, et al.
Publicado: (2022)

A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma
por: Kessler, Elizabeth R., et al.
Publicado: (2023)

Erratum to: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma
por: Sharma, Akanksha, et al.
Publicado: (2023)

Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
por: Krens, Stefanie D., et al.
Publicado: (2022)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2018)

Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
por: Tran, Benjamin Duy, et al.
Publicado: (2023)

Primary Head and Neck Tumour-Derived Fibroblasts Promote Lymphangiogenesis in a Lymphatic Organotypic Co-culture Model
por: Lugo-Cintrón, Karina M., et al.
Publicado: (2021)

Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation
por: Molina-Cerrillo, Javier, et al.
Publicado: (2020)

Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
por: Jansen, Caroline S., et al.
Publicado: (2023)

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2018)

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
por: Santoni, Matteo, et al.
Publicado: (2021)

Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_071a72u1fgq6543mmhukpj85ar